Press Interview Transcript complete- Secretary of Defense Chuck Hagel interview with Charlie Rose on November 19, 2014 on PBS: “ROSE: Mr. Secretary, thank you for the opportunity to visit with you at the Pentagon. Let me begin with the question of national security and how you perceive the biggest threats to America in some order […]
“We are living at one of these times in history where there is a confluence of threats and challenges. Like I don’t think we’ve ever seen before”, warns Hagel
Press Interview – Presenters: Secretary of Defense Chuck Hagel interview with Charlie Rose on November 19, 2014: “ROSE: Mr. Secretary, thank you for the opportunity to visit with you at the Pentagon. Let me begin with the question of national security and how you perceive the biggest threats to America in some order of […]
Entry Tax, Toll Tax on import of relief material exempted for further ten days:Rather
Srinagar, October 01, (Scoop News)-Government today granted ten days extension upto 10th October 2014 on the exemption of levy of Entry Tax and Toll tax on import of material, for relief and rehabilitation of the flood affected people of the State. Decision to this effect was taken at a higher level meeting convened here this […]
Yo Hillary! What’s your message?
Having name recognition doesn’t mean you’ve built a brand that connects with your audience. Take Hillary Rodham Clinton. Everyone knows who she is, but no one knows what she stands for, i.e., her brand is lackluster and she doesn’t have a message. Examining Hillary Clinton’s brand has less to do with her career as a […]
MolMed NGRhTNF ASCO New Data Show Significantly Extended Survival
A statistically significant 40% improvement of both overall survival and progression-free survival in a large population of patients, identified by a pre-specified analysis on the prior treatment-free interval, and who presented a very dismal prognosis was reported by MolMed S.p.A. (MLM.MI) this weekend, at the 50th ASCO annual meeting. These efficacy results were observed in […]
MolMed reports top line results of NGR-hTNF in the phase III trial in malignant pleural mesothelioma
MolMed S.p.A. (MLM.MI) today announced the results of the double-blinded, placebo-controlled Phase III trial of NGR-hTNF versus best investigator choice in 400 patients with malignant pleural mesothelioma who had previously failed a first-line chemotherapy. Despite not meeting its primary endpoint of improving overall survival (OS) in the entire population, the study showed a […]
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- 6
- …
- 14
- Next Page »